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ABSTRACT Blood coagulation in vivo is a spatially nonuniform, multistage process: coagulation factors from plasma bind to
tissue factor (TF)-expressing cells, become activated, dissociate, and diffuse into plasma to form enzymatic complexes on the
membranes of activated platelets. We studied spatial regulation of coagulation using two approaches: 1), an in vitro experimental
model of clot formation in a thin layer of plasma activated by a monolayer of TF-expressing cells; and 2), a computer simulation
model.Clotting in factorVIII- and factorXI-deﬁcient plasmaswas initiated normally, but further clot elongationwas impaired in factor
VIII- and, at later stages, in factor XI-deﬁcient plasma. The data indicated that clot elongation was regulated by factor Xa formation
by intrinsic tenase, whereas factor IXa was formed by extrinsic tenase on activating cells and diffused into plasma, thus sustaining
clot growth. Far from the activating cells, additional factor IXa was produced by factor XIa. Exogenously added TF had no effect on
the clot growth rate, suggesting that plasma TF does not contribute signiﬁcantly to the clot propagation process in a reaction-
diffusion systemwithout ﬂow. Addition of thrombomodulin at 3–100 nM caused dose-dependent termination of clot elongation with
a ﬁnal clot size of 2–0.2mm.These results identify roles of speciﬁc coagulation pathways at different stages of spatial clot formation
(initiation, elongation, and termination) and provide a possible basis for their therapeutic targeting.
INTRODUCTION
The function of blood coagulation is to prevent blood loss by
forming a ﬁbrin clot localized at the site of vascular injury (for
a review of coagulation, see Butenas and Mann (1)). Spatial
heterogeneity is an essential property of this system. The
coagulation process is initiated by extravascular tissue factor
(TF2)-expressing cells at the site of damage. Its propagation
requires assembly of enzymatic complexes on themembranes
of activated platelets, and it is tightly regulated by the in-
hibitors thrombomodulin and heparin expressed by endothe-
lial cells of the undamaged regions of vessel wall. Molecules
of activated coagulation factors dissociate from activating
cells, overpass some distance by diffusion from the site of
vascular damage to platelet membranes, and bind platelets to
form enzymatic complexes. These complexes in their turn
produce active factors, which diffuse further, resulting in a
self-sustained process of enzyme generation and clot growth.
At some stage, this process should be stopped to localize the
ﬁbrin clot and avoid thrombosis.
Themost widely used concept of coagulation is the cascade
model (2), picturing coagulation as a complex sequence of
enzymatic reactions. However, a number of recent studies
point out that, although it is correct for in vitro homogenous
experiments, this model seems not to account for some im-
portant aspects of in vivo hemostatic and thrombotic pro-
cesses (3,4). Indeed, different reactions of the coagulation
cascade occur at different locations: in plasma or on extra-
vascular cells, platelets, or endothelium. An adequate model
of hemostasis/thrombosis should correctly describe the role of
diffusion,which connects these ‘‘compartments’’. The impor-
tance of spatial heterogeneity and diffusion in the control of
blood coagulation is illustrated by studies of the diffusion
barrier for active factor transfer from TF-expressing cells to
platelets (5), of spatial propagation of coagulation from the
activating cells (6,7), and of hindered diffusion of factor (f) Xa
in platelet-rich thrombin (8).
Previously, we proposed an experimental in vitro model
utilizing time-lapse videomicroscopy to directly monitor
spatial clot formation in a thin layer of nonstirred plasma (9).
Using plasma from patients with a coagulation disorder,
hemophilia, we demonstrated that initiation of clot formation
in hemophilic plasma occurs normally, whereas elongation of
the clot is dramatically impaired (6). These results suggest that
two pathways of coagulation cascade, intrinsic and extrinsic
fX-activating complexes (tenases), are physically separated in
space, and intrinsic tenase functions to produce fXa far from
the activator, where extrinsic tenase is absent.
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The objective of this study was to systematically analyze
roles of extrinsic and intrinsic tenases in fX activation, and
roles of extrinsic tenase and fXIa in fIX activation during clot
formation in a reaction-diffusion system. Experimental and
computer simulation approaches were combined to compare
spatial clot formation in fVIII- and fXI-deﬁcient plasmas.
We were able to demonstrate that, despite the complexity
of coagulation cascade, for each individual stage of clot
propagation there is a single pathway of blood coagulation
that regulates it. Initiation of coagulation is regulated by
extrinsic tenase only and the clot propagation is controlled by
fXa generation via intrinsic tenase, whereas fIXa is primarily
formed by extrinsic tenase. At late stages of clot progression
far from the activator, additional fIXa is produced by fXIa.
The mechanism of clot localization upon thrombomodulin
addition was studied. These results provide a link between the
biochemical scheme of the cascade and the actual roles played
by individual pathways at different stages of the ﬁbrin clot
formation.
MATERIALS AND METHODS
Experimental methods
Materials
Human recombinant TF (INNOVIN) was purchased from Baxter (Deerﬁeld,
IL). Functional TF concentration was determined by ACTICHROME TF
chromogenic activity kit (American Diagnostica, Stamford, CT). FXIIa
inhibitor from corn seeds (CTI) was purchased from Enzyme Research
Laboratories (South Bend, IN). Rabbit lung thrombomodulin was from
Haematologic Technologies (Essex Junction, VT). Frozen pooled fVIII- and
fXI-deﬁcient and control normal plasmas were from George King Biomed-
icals (Overland Park, KS). Sodium citrate and lactic acid were from Sigma
(St Louis, MO).
Blood collection and plasma preparation
Blood from healthy donors and severe (fVIII , 1% of the normal level)
hemophilia A patients was collected into 3.8% sodium citrate (pH 5.5) at a
9:1 v/v ratio and processed as described (10). Brieﬂy, blood was centrifuged
at 1500 g for 25 min. Supernatant was centrifuged at 10,000 g for 5 min to
obtain platelet-free plasma. Its pH value was stabilized at 7.2–7.4 by lactic
acid treatment (11). Fresh-frozen fVIII- and fXI-deﬁcient and normal
plasmas were processed as described (7). There was no signiﬁcant difference
between clot formation in plasma obtained from hemophilia A donors and
commercially available fVIII-deﬁcient plasma.
Cell culture
A human fetal lung ﬁbroblast line was from the Research Institute of
Virology (Russian Academy of Medical Sciences, Moscow, Russia). Cells
were grown on polyethylene terephthalate (PET) ﬁlm slips (Joint Institute
for Nuclear Research, Dubna, Russia) placed on the bottom of 12-well plates
(Corning, Acton, MA), as described earlier (10). Human macrophages were
obtained as a result of the differentiation of monocytes (12) isolated from
mononuclear leukocyte preparations obtained by apheresis procedure
performed by the Research Blood Staff at the Holland Laboratory, American
Red Cross, under a protocol approved by the Institutional Review Board.
Primary culture of human aortic endothelial cells was purchased from
Cambrex (Walkersville, MD) and was used at passages 4 through 10. Cells
were grown on PET ﬁlm slips as described earlier (7).
Spatial clot growth
Spatial ﬁbrin clot growth was studied using a light-scattering video
microscopy system described previously (6). A microchamber was assem-
bled in a suspension cell culture nontreated 35-mm polystyrene petri dish
(Corning) around a 1-mm-thick glass slide (FisherBrand, Fisher Scientiﬁc,
Pittsburgh, PA) ﬁxed to its bottom. The glass slide edge, which formed a
vertical wall of the chamber, was wrapped around with a cell-coated PET
slip. Plasma was recalciﬁed by addition of 1 M CaCl2 at 2% v/v and rapidly
transferred into the assembled chamber. The light-scattering data were
monitored by digital microscopy; an image was captured every 30 s. All
experiments were performed at 37C.
Image processing
For each experiment, parameters of clot growth were determined on the basis
of video image of the growing clot, as described previously (10). Brieﬂy, a
perpendicular to the cell monolayer surface was drawn and plots of light
scattering versus distance from the activator (clot proﬁles) were calculated
(see, e.g., Fig. 1 A). For each proﬁle, the clot size was determined as a coor-
dinate where the light-scattering intensity was half-maximal. Clot growth
rate was determined as a mean slope of the plot of the clot size versus time in
the range of 10–30 min after the beginning of the experiment.
Modeling methods
Concepts of the model
The mathematical model of this study was designed to describe spatial
dynamics of clot formation in nonstirred recalciﬁed plasma activated by a
monolayer of TF-expressing cells at physiological temperature and ionic
composition (37C, pH 7.2–7.4, 2 mM Ca21, 150 mM NaCl). Model
equations (Eqs. S1–S50), initial concentrations (Table S1), rate constants
(Table S2), and diffusion coefﬁcients (Table S3) are supplied in the Sup-
plementary Material. No model parameters were adjusted, and only the values
reported in the literature were used. A typical model equation for a reagent in
plasma is shown below for fVIIIa:
@½VIIIa
@t
¼ DVIIIa3 @
2½VIIIa
@x
2 1
k
VIII;IIa
cat 3 ½VIII3 ½IIaF
K
VIII; IIa
M 1 ½IIaF
 hVIIIa3 ½VIIIa; (1)
where [VIIIa] ([VIII]) is the fVIIIa (fVIII) concentration, ½IIaF is the
free thrombin (not in complex with its substrates) concentration, DVIIIa
is the fVIIIa diffusion coefﬁcient, kVIII;IIacat andK
VIII;IIa
M are catalytic andMichaelis
constants of fVIII activation, and hVIIIa is the ﬁrst-order constant of fVIIIa
activity loss. For reagents located on the membranes of TF-expressing cells (TF,
VIIa-TF, and VII-TF), we used surface densities instead of volume concen-
trations and ordinary differential equations. An example for TF is given below:
dsTF
dt
¼ðkVIIa;TFa 3 ½VIIa3sTF  kVIIaTFd 3sFVIIaTFÞ
 ðkVII;TFa 3 ½VIIjx¼03sTF  kVIITFd 3sVIITFÞ; (2)
where sTF (sVIITF) is the TF (VIIa-TF) surface density, sFVIIaTF is the free
VIIa-TF density, ½VIIajx¼0 (½VIIjx¼0) is the concentration of fVIIa (fVII)
near the activator, kVIIa;TFa (k
VII;TF
a ) and k
VIIaTF
d (k
VIITF
d ) are association and
dissociation constants, respectively, of the VIIa-TF (VII-TF) complex. Thus,
the mathematical model is biphasic: it contains reagents on the activating
surfaces and in plasma. To link these phases, boundary conditions are used.
An example of boundary condition is given below for fVIIa:
DVIIa3
@½VIIa
@x

x¼0
¼ kVIIa;TFa 3 ½VIIajx¼03sTF  kVIIaTFd
3sFVIIaTF

: (3)
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A mathematical model of almost 30 differential equations containing
.100 parameters from the literature required a special approach in the
development. For many rate constants of coagulation reactions, values
reported by different groups differ by orders of magnitude. If these values
were chosen randomly, the behavior of such a model would be unlikely to
agree with experimental results. On the other hand, voluntary adjustment of
parameters to describe several selected experiments does not guarantee
correctness of the obtained model either. Therefore, to create an adequate
model, we initially developed and validated models of individual reactions
of the coagulation cascade, in particular for the TF pathway inhibitor (TFPI)
pathway (13) and for intrinsic tenase (14). Subsequently, we simulated
larger subsystems using, for validation, experimental data of Ovanesov et al.
(6,7,10) Diamond and Anand (15), Matveyev and Domogatsky (16), Hairer
et al. (17), Lawson et al. (18), Gailani and Broze (19), Butenas et al. (20), and
Giesen et al. (21). The range of kinetic parameters in these simulations was
strictly limited to the values reported in experimental studies; no optimi-
zation of these values was done. Comparing increasingly more complex
systems with experiments, the ﬁnal version of the model for clotting in
plasma was developed.
Assumptions about procoagulant membranes
We assumed that procoagulant surface for the assembly of coagulation
enzymatic complexes is primarily provided by activated platelets. Of
platelet-secreted substances, secretion of fV(a) only was included in the
model. Platelet-secreted fV(a) is a partially proteolyzed form of fV with
;30–50% of the activity of fully activated fVa (22); we assumed it to be an
equimolar mixture of fVa and fV. Except for thrombin, platelet activators
were omitted, as collagen was absent in the simulated experiments, and other
physiological agonists do not cause signiﬁcant alpha-granule secretion and
procoagulant surface exposure in the absence of cell-cell contacts (23). On
the basis of recent studies (24,25), we assumed that only a small fraction
(d ¼ 4%) of thrombin-activated platelets can speciﬁcally bind coagulation
factors and support membrane-dependent procoagulant reactions. Depen-
dence of d on thrombin concentration (24) was ignored in the model. The
numbers of binding sites per platelet and the effective constants of platelet-
dependent reactions (previously determined assuming all platelets to be
identical) were corrected by the factor of d or 1/d, as indicated in Table S2.
Platelet activation, secretion, surface exposure, and binding of factors were
assumed to be rapid (14). Activated platelets shed microparticles, which
bind coagulation proteins with parameters similar to those of platelets. In the
model, we did not distinguish platelets and platelet-derived microparticles
and used a common Na variable with dimensionality of nM, which described
all membranes available for the binding of coagulation factors. Ni, the initial
effective procoagulant activity of membranes in plasma represented by
circulating microparticles, lipoproteins, etc., was estimated by comparing
experiments and simulations of clot formation in ultracentrifuged (7) plasma
titrated with platelets (data not shown).
FIGURE 1 Normal ﬁbrin clot formation. (A) Time course of evolution of light-scattering proﬁles of the clot obtained from the complete series of light
scattering images. Clots were formed on the surface of a ﬁbroblast monolayer in the presence of 0.2 mg/ml CTI as described in Materials and Methods. (B)
Computer simulation of clot formation: ﬁbrin proﬁles, corresponding to the experimental light-scattering proﬁles in A. Simulations were performed using the
model (Eqs. S1–S50) with parameters listed in Tables S1–S3 (see Supplementary Material). Fibroblast monolayer density in the model was 1000 cells/mm2.
(C) Computer simulation of spatial clot formation: thrombin proﬁles. Simulations were performed as in B. A movie for this ﬁgure is available (see Supple-
mentary Material).
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Assumptions about diffusion
Diffusion coefﬁcients of coagulation factors within ﬁbrin clot were assumed
to be the same as in liquid plasma due to the high clot porosity (for a detailed
theoretical analysis see Oliver et al. (26)); this was conﬁrmed experimentally
by Scott and Coleman (27). Coagulation factors can bind to platelets, or
ﬁbrin, or other factors, and their diffusion is then slowed down. For the
majority of factors, the portion of bound factor is small, and a diffusion
operator was applied to the total protein concentration [F]. However, for
fXa, thrombin, and fXIa this assumption can be incorrect, as their binding to
platelets, substrates, or ﬁbrin could be signiﬁcant. For these factors, diffusion
of free factor [FF] only was considered.
Other model assumptions
A number of reactions in the model were described by phenomenological
equations, in particular, thrombin activation of fXI, TF-independent fVIIa
activation of fX and fIX (modeled as pseudo-second-order reactions with
rate constants proportional to the activated platelets concentration), and
TFPI pathway (13). Fibrinogen cleavage was described by a Michaelis-
Menten reaction with product inhibition (28). The equation for prothrom-
binase was obtained by analogy with a previously reported equation for
intrinsic tenase (14) assuming that fXa binds to platelet-bound fVa (29) and
platelet-bound prothrombin is activated by the Xa-Va complex in a two-
dimensional reaction:
d½IIa
dt
¼ k
local II;XaVa
cat 3 ½Xa VaB3 ½IIB
Klocal II;XaVaM 3Na=k
: (4)
For the activated protein C (APC)-independent action of phosphatidyl-
serine (PS), we used a mechanism suggested earlier (30) and assumed that
PS binds fVa in competition with fXa, and makes it accessible for APC.
Intrinsic tenase inactivation by PS was described using a hypothesis that
membrane-bound fVIIIa is directly and reversibly inhibited by PS (31). We
included in the model activation of fV, fVIII, and fVII by thrombin only,
ignoring their activation by fXa and other factors, because contribution of
these slow membrane-dependent reactions appears not to be signiﬁcant
under the conditions of this study (21). Artiﬁcial contact activation from
laboratory test tubes was simulated by fIXa inﬂow (32). The assumption of
Michaelis-Menten kinetics is valid only for one-substrate reactions when
enzyme concentration is much less than that of substrate. For reactions of
coagulation, this condition does not always hold. Thus, for activation of a
substrate Si by an enzyme E, which catalyzes the conversion of n substrates
competing for the same active site, and concentration of which can be both
below and in excess of that of the substrates, we used the equation:
d½Si
dt
¼  k
i
cat3 ½E3 ½Si
K
i
M  11 +
n
j¼1
½Sj
K
j
M
 !
1 ½E
: (5)
This equation was obtained from the steady-state equations for transitory
complexes. The derivation results in an equation identical to Eq. 3, with free
substrate concentrations in the denominator, which can be substituted with total
concentrations if any of the following conditions holds for each ith substrate:
½E  ½Si; ½E  KiM; ½Si  KiM: (6)
We assumed that the activating surface is an inﬁnitely thin layer of TF.
This assumption is valid as long as a high-density monolayer of TF-bearing
cells is used. Further, one-dimensional an assumption was used for the
model, because the microchamber is completely covered with activator
along the height dimension, and its width exceeds severalfold the observed
clot lengths. The value of contact activation by the walls of the experimental
chamber was estimated on the basis of the difference between clot growth
rate in the absence and in the presence of CTI, and on the basis of activated
partial thromboplastin time elongation upon addition of 0.2 mg/ml CTI to
plasma (data not shown).
Computation
To integrate numerically the set of partial differential equations, we used
the embedded Runge-Kutta-Fehlberg method of the 2nd (3rd) order (33),
which was adapted for partial differential equations (3). The program was
developed in Watcom C/C11 10.0. Calculations were carried out on
the 0–3 mm interval.
RESULTS
The reaction-diffusion model of spatial
clot formation
Experimental and modeling methods used in this study are
illustrated in Fig. 1. Light-scattering proﬁles obtained from
the series of images of clotting in normal plasma on ﬁbroblast
monolayer are shown in Fig. 1 A in a three-dimensional plot.
Fig. 1,B andC, shows theoretical ﬁbrin and thrombin proﬁles,
respectively, obtained using the mathematical model. Light-
scattering intensity is linearly proportional to ﬁbrin concen-
tration in the clot (7), and thus ﬁbrin concentration obtained
by simulations can be compared with experimentally ob-
served light-scattering intensity. Upon activation, thrombin
concentration in the model near the activator was rapidly
increased, and then decreased slowly. Thrombin proﬁles
initially had diffusion-like form; subsequently, the front edge
of the thrombin proﬁle was transformed into a pulse, which
started moving into the bulk of plasma. To characterize clot
formation quantitatively, we used initiation time tin (time of
half-maximal ﬁbrinogen cleavage near the activator) and clot
growth rate vclot (the slope of the clot size versus time plot).
Using the mathematical model, we studied correlation of
tin and vclot with parameters usually used to characterize
thrombin generation. Concentrations of coagulation factors
and values of kinetic constants were varied into 10% or 200%
of their normal values and changes in clotting parameters were
determined (not shown). The correlation analysis revealed
(Table 1) that the rate of clot elongation vclot correlated
signiﬁcantly and positively with maximal thrombin IIamax,
thrombin potential PIIa, maximal rate of thrombin generation
vmax (R ¼ 0.68–0.83), and did not correlate with clot time tclot
(time of the half-maximal ﬁbrinogen cleavage), lag time tlag
(time to achieve 10 nM of thrombin), thrombin maximum
time tmax (R¼ –0.32 to –0.51). On the contrary, initiation time
tin did not correlate with IIamax, PIIa, vmax (R¼ –0.07 to –0.16)
and correlated positively with tclot, tlag, and tmax (R ¼ 0.74–
0.78). There was no correlation between parameters depicting
initiation (tin) and growth (vclot) of the clot (R ¼ –0.17).
Contribution of intrinsic and extrinsic tenases
to spatial clot formation
To examine relative contributions of the intrinsic and
extrinsic tenase complexes to clot formation, studies of clot
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growth in fVIII-deﬁcient plasma were undertaken. The clot
size versus time plots in Fig. 2, A (experimental) and B
(theoretical), show dose-dependent increase of the clot
growth rate upon supplementation of hemophilia A plasma
with normal plasma. The curves demonstrate that initiation
of coagulation was not affected by fVIII supplementation,
whereas clotting propagation is regulated by the presence/
concentration of intrinsic tenase.
As a visual representation of this conclusion, Fig. 2, D–F,
shows concentration proﬁles of fXa produced by either
extrinsic tenase (VIIa-TF), intrinsic tenase (IXa-TF), or the
total fXa, which were obtained using a computer simulation
model. Although extrinsic tenase-produced fXa was located
near the activator and rapidly decayed (Fig. 2D), the intrinsic
tenase complex in plasma controlled the fXa formation and
the clotting propagation from the activator (Fig. 2 E),
accounting for all spatial effects (compare Fig. 2, E and F).
Whereas at 4min after initiation, the ratio of intrinsic/extrinsic
total fXa (integrals from the fXa concentration over distance)
was 0.44, at 20 min it was 2.83 and rapidly increased. Thus,
during the propagation phase, fXa formation by intrinsic
tenase is rate-limiting.
Contribution of fXI activation by thrombin far from
the TF-expressing surface
The limiting component of intrinsic tenase (15), fIXa, can be
produced via two pathways, which generate either extrinsic
tenase or fXIa. The latter factor can also be generated by
thrombin in a feedback reaction (34). To determine the roles
and contributions of these pathways, we studied clot forma-
tion in fXI-deﬁcient plasma. To make the possible fXIa con-
tribution more distinctive, macrophages, known to carry less
TF than ﬁbroblasts (7), were used as activating cells. Experi-
mental (Fig. 3 A) and theoretical (Fig. 3 B) clot size versus
time plots show that clot formation in fXI-deﬁcient plasma
(2) was impaired in comparison with control (1), although
the pattern was distinctive from that of fVIII-deﬁcient
plasma (3). Differences in normal and fXI-deﬁcient plasmas
were seen only at;25 min after the beginning of the experi-
ment, at;0.7 mm from the activator (;7 min and;0.3 mm,
respectively, for fVIII deﬁciency). However, at these later
stages, formation of the clot was slowed down to an extent
similar to that in fVIII deﬁciency, as can be seen in Fig. 3 C,
where the rate of clot elongation during the 30- to 40-min
interval is shown as a function of fXI concentration. To
summarize, in contrast to the generation of fXa, fIXa for-
mation by extrinsic tenase appears to control clot propagation,
with the exception of the fXIa contribution at later stages.
Computer simulations in Fig. 3, D and E, illustrate the
contribution of extrinsic tenase and fXIa, respectively, into
fIX activation in normal plasma. During the beginning of the
propagation period, fIXa, in contrast to fXa, is mainly
produced by extrinsic tenase (compare Fig. 3, D and F) and
delivered to plasma by diffusion. Only far from the activator,
fIXa generated by fXIa becomes signiﬁcant (Fig. 3 E). This
difference between fIXa and fXa seems to be caused by the
low rate of fIXa inhibition in plasma, which allows its
prolonged diffusion. To test this, the fIXa diffusion coefﬁ-
cient in the model was decreased 100-fold, resulting in an
impairment of the clot formation (Fig. 3 B, 5) and conﬁrming
this suggestion. On the other hand, a 100-fold decrease of
fXa diffusion coefﬁcient had no effect on clot growth rate in
the propagation phase, whereas initiation of coagulation was
even signiﬁcantly accelerated (Fig. 3 B, 4). Analysis of the
fXa concentration proﬁles (not shown) suggested that this
acceleration was due to the accumulation of fXa near the
activating surface because of slowed diffusion. A 100-fold
decrease of the diffusion coefﬁcients of zymogens fIX and
fX had almost no effect on clot formation (data not shown).
Inhibition of clot growth by thrombomodulin
The above results suggest a mechanism of the diffusion-
mediated control of blood coagulation. However, under any of
the studied conditions, termination of clot propagation was
never observed in our experimental model within the
reasonable time-span of the experiment (1–2 h). Moreover,
in some experiments on hemophilia A plasma, clot growth
was monitored for .5 h, and the propagation of the clot still
did not stop despite the small clot growth rate (data not
shown). If we assume the spatial clot growth model to
represent hemostatic or even thrombotic clot formation, this
result provides some trouble in interpretation since the
coagulation process in vivo is expected to be ﬁnite and
localized. One of the most important components of hemo-
stasis, which is absent in the in vitro system of this study, is the
fact that the damaged vessel wall is surrounded by undisturbed
endothelium that is known to have several surface anticoag-
ulants. To introduce a possible effect of intact endothelium
into our system, rabbit lung thrombomodulin was premixed
TABLE 1 Correlation matrix for parameters of spatial clot
formation and thrombin generation
tin vclot
tclot 0.85 0.22
tlag 0.83 0.32
tmax 0.82 0.47
vmax 0.18 0.84
PIIa 0.11 0.57
IIamax 0.18 0.78
tin 0.17
Clot formation was simulated as described in the legend to Fig. 1; ﬁbroblast
density was 1000 cells/mm2. During each simulation, one of the following
concentrations/constants was set to either 10% or 200% of its normal value:
sVIIaTF, [VIIa], [VII], [IX], [X], [II], [Fg], [VIII], [V], [PC], [PS], [XI], [AT-
III], [a2M], [TFPI], k
VII; IIa
cat , k
IX; VIIaTF
cat , k
IX; XIa
cat , k
X;VIIaTF
cat , k
X; IXaVIIIa local
cat ,
klocal II;XaVacat =ðKlocal II;XaVaM =kÞ, kVIII; IIacat , kV; IIacat , kPC; IIacat , kXI; IIacat , kN; IIacat . The
same simulations for thrombin generation initiated by 25 pM TF were
performed using a homogenous version of the mathematical model, where
reaction-diffusion partial differential equations were substituted with ordi-
nary ones. Pearson correlation coefﬁcients were then calculated for the
obtained data sets.
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with plasma at concentrations from 3 to 100 nM. This resulted
in a complete, yet dose-dependent, termination of the clot
growth (Fig. 4 A), yielding a ﬁnal clot size of 0.2–1 mm (Fig. 4
B). The solid line in Fig. 4 B shows model simulations, which
agree well with the experiments. These results provide
experimental evidence of the localizing effect of thrombo-
modulin in the spatial clotting process.
Study of possible role of blood-borne TF in
clot formation
Effect of exogenously added TF
In recent years there was a considerable debate about the
possible role of circulating TF activity (known as blood-
borne TF) in clot initiation and growth (35,36). To evaluate
FIGURE 2 Contribution of intrinsic and extrinsic tenases to spatial clot formation. Clots were formed on the surface of a ﬁbroblast monolayer, as described
in Materials and Methods. (A and B) Clot size versus time plots of clot formation in the plasma of a hemophilia A donor supplemented with normal plasma,
from (A) a representative experiment (out of a total of four) and (B) the respective simulation. Normal plasma was at 0, 1%, 5%, 10%, 20%, 40%, and 100% v/v
(bottom to top). (C) The rate of spatial clot growth in hemophilia A plasma versus concentration of added normal plasma, with experiments represented by
symbols and simulations by the solid line. Mean values 6 SD are shown, n ¼ 4. (D–F) Simulated proﬁles of fXa during clot formation in normal plasma
produced by (D) extrinsic tenase, (E) intrinsic tenase, and (F) both. A movie for this ﬁgure is available (see Supplementary Material).
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the possible contribution of blood-borne TF to clot formation
in the spatial model, we added relipidated recombinant TF
to plasma at subpicomolar concentrations. Fig. 5 A shows
typical images of clot formation in the presence of TF. The
rate of clot growth was not signiﬁcantly affected by TF (Fig.
5 B). However, in the presence of TF, plasma began to clot
throughout the reaction volume independently of the acti-
vating cell monolayer. The time of the plasma clotting was a
FIGURE 3 Contribution of fXI activation by thrombin far from the TF-expressing surface. Clots were formed on the surface of a conﬂuent macrophage
monolayer as described in Materials and Methods. Simulations were performed as described for Fig. 1, except that activation was by ﬁbroblast monolayer with
a density of 250 cells/mm2. (A and B) Clot size versus time plots of clot formation in normal (1), fXI-deﬁcient (2), and fVIII-deﬁcient (3) plasmas, from (A) a
representative experiment (out of four total), and (B) the respective simulation. Dotted lines in B show computer simulations of clot growth in normal plasma,
where diffusion coefﬁcients of fXa (4) or fIXa (5) were decreased 100-fold. (C) The rate of spatial clot growth far from the activator (determined on the 30- to
40-min interval) in fXI-deﬁcient plasma versus concentration of supplemented normal pooled plasma, with experiments represented by symbols and
simulations by the solid line. Mean values6 SD are shown, n¼ 2–4. (D–F) Simulated proﬁles of fIXa during clot formation in normal plasma produced by (D)
extrinsic tenase, (E) fXIa, and (F) both.
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dose-dependent function of TF (Fig. 5 B). Computer simu-
lations of clot growth experiments gave similar results: TF in
the reaction volume had almost no effect on clot growth (data
not shown). Together with our previous report that incuba-
tion of plasma with anti-TF antibodies did not inhibit spatial
clot growth (7), these data indicate that plasma-associated TF
does not contribute to clot formation in the absence of ﬂow,
yet it may contribute to activation of coagulation.
DISCUSSION
The roles of the extrinsic and intrinsic tenase complexes, fXI,
and the protein C pathway in blood coagulation were studied
in a reaction-diffusion experimental model of spatial clot
formation, complemented by analysis utilizing a mathemat-
ical model. The data demonstrate the following:
1. Intrinsic and extrinsic tenases play different roles at
different stages of clot formation. fXa generated by
extrinsic tenase functions only near TF-expressing cells
and is rapidly inhibited nearby, whereas clotting far from
the activator requires fX activation by intrinsic tenase.
2. Functions of fIXa and fXa in the propagation of coagu-
lation are also different. In contrast to fXa, fIXa produced
by extrinsic tenase can diffuse from the activator, allow-
ing intrinsic tenase assembly and clot expansion.
3. At long distances from the TF-expressing cells, addi-
tional fIXa is produced by fXIa, generated by thrombin
in a feedback reaction.
4. Thrombomodulin is able to terminate clot expansion and
to localize clotting in a dose-dependent manner.
These results were obtained experimentally, and a com-
puter simulation model was used primarily for their inde-
pendent conﬁrmation and better insight into the mechanisms
allowing separate monitoring of factor activation by different
pathways, change of diffusion coefﬁcients, etc.
The results of this study were obtained in an in vitro model
system designed to analyze the signiﬁcance of diffusion and
spatial heterogeneity in coagulation. Like other in vitro
models such as the thrombin generation assay (37), our
system does not correspond speciﬁcally to either physiolog-
ical or pathological coagulation, in contrast to more special-
ized in vivo, ex vivo, or in vitro models of thrombus
formation (38–40). Thus, the conclusions about the roles of
diffusion and of speciﬁc reactions at different stages of clot
formation obtained in this model are general and should be
applicable for both hemostasis and thrombosis.
A positive correlation (Table 1) between parameters of
spatial clot formation in the reaction-diffusion model and
parameters of homogenous thrombin generation demon-
strated using the computer model indicates a functional
similarity and provides a possible link between these two
models. Indeed, in the thrombin generation assay, complete
plasma clotting is rapidly catalyzed by initial traces of
thrombin, before the detectable burst of thrombin generation
occurs; still, it is the degree of generated thrombin that
correlates with bleeding and thrombotic tendencies (37).
Thus, physiological interpretation of the thrombin generation
assay may seem unclear: why do we need all this thrombin
when the clot is already formed? In a spatial reaction-
diffusion model, this ‘‘superﬂuous thrombin’’ paradox could
be solved, as active factors could diffuse to nearby locations
where clotting has not yet occurred (37). It should be noted
that correlation of spatial clot formation and thrombin
generation parameters does not mean complete equivalency
of these methods. For example, many aspects of clot for-
mation in a reaction-diffusion system, such as termination of
clot expansion, cannot be analyzed in a thrombin generation
assay.
Previously, we showed that the propagation stage of
spatial clot formation in hemophilia A and B plasmas is
impaired, suggesting that spatial clot enlargement is con-
trolled by fXa production by intrinsic tenase (6). Another
FIGURE 4 Clot growth termination and regulation of ﬁnal clot size by
thrombomodulin. Experiments and simulations were performed as described
for Fig. 1. (A) Experimental clot size versus time plot for clot formation in
normal plasma upon addition of thrombomodulin at 0 (n), 10 (:), and 100
(n) nM. (B) Final clot size is shown as a function of the concentration of
thrombomodulin added, for experiments (symbols , h, s and n indicate
three different donors) and simulations (solid line). A movie for this ﬁgure is
available (see Supplementary Material).
1496 Panteleev et al.
Biophysical Journal 90(5) 1489–1500
group used thrombin generation activated by TF-bearing
monocytes in a reconstituted system of coagulation proteins
and platelets to demonstrate that fIXa and fXa are required
for the ‘‘priming’’ of coagulation and for thrombin gener-
ation, respectively (5). They hypothesized that extrinsic
tenase-produced fXa initiates coagulation, but is conﬁned to
TF-expressing cells because of its inhibition in plasma,
whereas slowly inhibited fIXa can bind platelets to form
intrinsic tenase. However, without spatial heterogeneity this
concept might not be fully applicable, because fXa inhibition
might not be rapid enough to prevent it from reaching nearby
platelets, and stirring in this system allows enhanced fXa
distribution to platelets. In this study, a system without
stirring was used. Clot formation near the activator (;0.2
mm) was regulated by extrinsic tenase (no difference be-
tween control and fVIII deﬁciency), whereas fXa formation
farther away required intrinsic tenase (impairment in fVIII
deﬁciency). However, this intrinsic tenase was formed by
extrinsic tenase-produced fIXa but not by fXIa (no impair-
ment in fXI deﬁciency). Only at distances of .;0.8 mm
from the activator did fXIa contribute to clot formation. The
distance of effective diffusion of an enzyme is proportional
to
ﬃﬃﬃﬃﬃﬃﬃﬃ
D=h
p
, where D is the diffusion coefﬁcient, and h is the
ﬁrst-order inhibition constant. Diffusion coefﬁcients of fIXa
and fXa are similar, whereas their inhibition rates by plasma
inhibitors are;1 min1 and;0.03–0.1 min1, respectively.
Thus, their distances of effective diffusion should differ
three to sixfold, in agreement with our results. Furthermore,
decreasing fIXa diffusion coefﬁcient 100-fold resulted in
clot formation impairment approaching that in factor VIII-
deﬁcient plasma. On the other hand, a 100-fold decrease of
fXa diffusion coefﬁcient did not decrease the clot growth
rate, and initiation phase was even shortened. This also indi-
cates that fXa diffusion is not important for the propagation
of coagulation, whereas fIXa diffusion is rate-limiting. A
recent study (8) demonstrated that effective diffusion of fXa
in ﬁbrin clot is slow, being dramatically (by three orders of
magnitude) slowed down in platelet-ﬁbrin clot, most prob-
ably due to the efﬁcient binding of fXa to platelets. Our
results demonstrating that clot propagation in a spatial model
FIGURE 5 Effect of exogenously added TF on clot formation. CTI-inhibited normal pooled plasma was supplemented with relipidated recombinant TF and
placed in contact with monolayers of lung ﬁbroblasts or endothelial cells. (A) Light-scattering time-lapse images of clot formation initiated by ﬁbroblast
monolayers. Addition of TF induced ‘‘spontaneous’’ (independent of ﬁbroblasts) clot formation in all areas of the microchamber. Scale bar, 1 mm. (B) Effect of
TF concentration on clot growth rate. Clot formation was activated by either ﬁbroblasts (d) or endothelial cells (n). (C) Effect of TF on spontaneous clotting
lag time. To calculate spontaneous clotting lag time, an area 33 3 mm2 located at least 3 mm away from the surface of TF-bearing cells was selected on the ﬁrst
frame, and the mean light-scattering intensity within this square area was plotted versus time. The lag time of spontaneous clot formation was deﬁned as the
time interval required for the mean light scattering to reach half-maximal value. Mean values 6 SD are shown, n ¼ 2.
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is mediated by fIXa diffusion and other mechanisms rather
than by fXa diffusion are in line with that report. That study
(8) also suggested that diffusion of zymogens fIX and fX in
ﬁbrin clot is also slowed down. Computer simulations in our
study with 100-fold decrease of the diffusion coefﬁcients of
fIX and fX showed no effect of the slowed diffusion of clot
formation. This seems to be at least partially due to very slow
consumption of these zymogens during coagulation (15), so
that they are always present in the reaction volume and their
diffusion ﬂux is small and nonessential.
The role of fXI in coagulation has been a subject of debate
for a long time (41). It activates fIX and its deﬁciency is
associated with a tendency to bleed. fXI can be activated by
fXIIa, a contact pathway factor, but fXII deﬁciency is not
associated with a bleeding tendency and the contact pathway
is assumed not to function in physiological hemostasis.
Some studies have shown that fXI is slowly activated by
thrombin in the absence of cofactors, and that this reaction is
accelerated 2000-fold in the presence of dextran sulfate (34).
Other works demonstrated that in plasma this reaction is
ineffective, which was ascribed to inhibition by ﬁbrinogen
(42). One study suggested that fXI activation by thrombin
results in additional thrombin preventing the clot from
ﬁbrinolysis (43). Later, this reaction was shown to be stim-
ulated by activated platelets (41,44), and fXIa was shown to
increase thrombin generation, especially at low TF and in the
presence of platelets (45,46). However, it seems unclear
whether a small effect on thrombin generation is able to
explain the signiﬁcance of fXI illustrated by bleeding asso-
ciated with its deﬁciency, hemophilia C. Our previous theo-
retical analysis suggested that fXI activation by thrombin
may be important for the spatial propagation of coagulation
(3). In our study, clot formation in fXI-deﬁcient plasma was
impaired far from the activator, conﬁrming this hypothesis.
These results provide a possible explanation of the signif-
icance of fXI: although its activation by thrombin is slow,
this reaction and additional fIXa formed by fXIa become
important during the formation of large clots, in the regions
remote from TF-expressing cells. It should be noted that
these results were obtained under conditions in which the
contribution of extrinsic tenase is maximal (conﬂuent mono-
layers of ﬁbroblasts and macrophages) and intrinsic tenase
assembly and fXI activation by thrombin are minimal (platelet-
free plasma). Under in vivo conditions, the contribution of
intrinsic tenase and fXIa-mediated feedback to clot propa-
gation could be even more signiﬁcant. On the other hand,
self-sustained autocatalytic propagation of clotting seems not
to be desirable in vivo, and fXI activation by thrombin may
be potentially dangerous (40). In such cases, speciﬁc thera-
peutic inhibition of fXI can slow down thrombus propaga-
tion without affecting the initiation of hemostasis (Fig. 3, A
and B).
The inhibitory effect of thrombomodulin, a cofactor of
thrombin stimulating APC generation, has been studied in
thrombin generation assays (47). For a long time it was
hypothesized to participate in localization of the coagulation
FIGURE 6 Schematic representation of the reaction-diffusion model of coagulation. Blood coagulation is activated by TF-expressing cells (on the left) and
propagates into the bulk of plasma. Coagulation near the activator (initiation) is determined by fXa production by extrinsic tenase located on TF-expressing
cells. fXa is rapidly inhibited and does not diffuse at long distances. Far from the activator (propagation) it is formed by intrinsic tenase. The limiting component
of intrinsic tenase, fIXa, is still produced by extrinsic tenase, because it is inhibited slowly and can diffuse efﬁciently. During further clot elongation, additional
fIXa production by the fXIa-mediated long-range feedback becomes essential. Finally, clot formation is terminated because of the action of thrombomodulin: in
a potent negative feedback, the thrombin-thrombomodulin complex produces APC, which stops thrombin formation by cleaving fVa and fVIIIa.
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process (48). A recent study in a murine model of FeCl3-
induced carotid artery thrombosis (39) has actually shown
that, indeed, in mice with a functional thrombomodulin
defect, complete occlusion of the artery occurred in 80% cases
(27% in control), andmean time of occlusionwas twofold less
than that in control. In our study, we analyzed the effect of
thrombomodulin in a reaction-diffusion spatial system. To
our knowledge, this work was the ﬁrst to directly demonstrate
that thrombomodulin is able to localize clot expansion in a
dose-dependent manner. Although thrombomodulin at 30–
100 nM affected both the initiation and propagation phases,
clot formation at 3–10 nM of thrombomodulin stopped at a
distance of 1–2 mm from the activator without signiﬁcant
effects on the initiation phase. In addition to demonstrating a
possible role of thrombomodulin in physiological hemostasis,
this result indicates that thrombomodulin can be therapeuti-
cally used to suppress thrombus propagation with minor
adverse effects on the initiation of hemostasis. Such an ap-
proach seems to be beneﬁcial compared with therapy using
such anticoagulants as heparin, which inhibits all stages of
clot formation and may lead to hemorrhage.
Several recent studies identiﬁed the presence of TF protein
and TF activity in blood and plasma (36,49). It was found to
accumulate in ex vivo thrombi (38) and it was proposed that
this blood-borne TF is essential for thrombus growth, because
diffusion of coagulation factors in ﬁbrin, and especially
in platelet-ﬁbrin clots, is slow (8). However, other studies
challenged this concept (35,50).We assessed the possible role
of blood-borne TF in clot growth by adding relipidated
recombinant TF to normal plasma. TF had no effect on clot
growth from the activating cell monolayer, but stimulated
clotting of the whole volume in a dose-dependent manner
(Fig. 5). The same result was obtained in the computer model.
Taken together, these data indicate that TF activity in plasma
is unlikely to contribute to spatial clot formation in the
reaction-diffusion system to any signiﬁcant extent. Thus,
transition from the homogeneous model of coagulation to the
spatial clot growth model appears not to increase the role of
blood-borne TF: diffusion of fIXa and fXI activation by
thrombin are effective enough tomake clot enlargement rapid
and independent of TF possibly present in plasma. However,
this result may become invalid in the reaction-diffusion-
convection models of thrombus formation because of the
accumulation of blood-borne TF in growing thrombus due to
the presence of blood ﬂow and hindered diffusion of coagu-
lation factors in platelet-rich thrombi.
The conclusions of this study can be summarized in a
spatial reaction-diffusion concept of the coagulation regula-
tion presented in Fig. 6. Clot formation in this model is
divided into three stages: initiation, spatial propagation (or
expansion), and termination. Each of the consecutive stages
is controlled by a speciﬁc pathway: 1), fXa production by
extrinsic tenase; 2), fIXa diffusion and fXa generation by in-
trinsic tenase, followed at later stages by fIX activation in the
fXI-mediated feedback; and 3), thrombomodulin-dependent
protein C pathway. The novelty of this mechanism is the in-
troduction of the conception of spatial heterogeneity into the
basic scheme of the coagulation cascade, and the attempt to
determine the roles of the speciﬁc pathways of the cascade at
different temporal and spatial stages of clotting. In particular,
this model may be useful in speciﬁc therapeutic targeting of
different stages of hemostatic and thrombotic processes.
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